25 completed, 5 terminated, 2 unknown, 1 active not recruiting. 26 Phase 1, 8 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 23, Terminated 2, Unknown 1 |
| Phase 2 | 8 | Terminated 4, Completed 2, Active not recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Unknown 1 |
Follow rhoA GTP-Binding Protein: new trials by email Literature Review of rhoA GTP-Binding Protein trials Research Report on rhoA GTP-Binding Protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) Rezpegaldesleukin, Placebo - Alopecia Areata | Phase 2 | Completed | Nektar Therapeutics | 94 | 2024-04-02 | 2026-09-18 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo - Moderate to Severe Atopic Dermatitis | Phase 2 | Active not recruiting | Nektar Therapeutics | 396 | 2023-11-15 | 2026-08-21 |
| Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101 NM-101, Placebo - Parkinson Disease | Phase 1 | Unknown | Neuramedy Co. Ltd. | 56 | 2023-05-10 | 2023-03-30 |
| Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis ALXN2050, Placebo - Generalized Myasthenia Gravis, Myasthenia Gravis | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 70 | 2022-04-27 | 2025-01-09 |
| Study of ALXN2050 in Participants With Hepatic Impairment ALXN2050 - Impaired Hepatic Function, Healthy | Phase 1 | Terminated | Alexion Pharmaceuticals, Inc. | 26 | 2022-04-07 | 2025-03-19 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) ALXN2050, Placebo - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2022-01-14 | 2025-10-15 |
| Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants ALXN2050, Cyclosporine, Tacrolimus - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 61 | 2022-01-11 | 2023-04-04 |
| Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia ALXN1830, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2022-01-01 | 2022-02-11 | |
| Study of ALXN2050 in Healthy Adult Participants of Japanese Descent ALXN2050, Placebo - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 20 | 2021-07-09 | 2022-12-09 |
| Study of ALXN2050 in Participants With Renal Impairment ALXN2050 - Renal Impairment, Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 40 | 2021-07-08 | 2023-09-29 |
| Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants ALXN2050, Fluconazole, Rifampin - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 16 | 2021-06-07 | 2026-07-16 |
| Study of Radiolabeled ALXN2050 in Healthy Adult Males [14C]-ALXN2050 - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 9 | 2021-04-12 | 2023-01-25 |
| A Study of the Cardiac Effects of ALXN2050 in Healthy Adults ALXN2050, ALXN2050-matching Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 39 | 2020-12-12 | 2021-12-29 |
| Study of the Metabolism of Danicopan in Healthy Adults Danicopan: Powder-In-Capsule 1, Danicopan: Powder-In-Capsule 2, Danicopan: Tablet - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 24 | 2020-10-20 | 2022-04-15 |
| Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults ALXN1840 - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 48 | 2019-07-04 | 2023-08-02 |
| A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants. SHP643 - Healthy Volunteers | Phase 1 | Completed | Shire | 190 | 2019-05-14 | 2020-12-08 |
| A Study of Multiple Doses of ALXN2050 in Healthy Adults ALXN2050, Placebo - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 45 | 2019-01-07 | 2021-09-17 |
| A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults Danicopan, Cyclosporine, Tacrolimus - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 72 | 2018-07-27 | 2021-11-05 |
| A Study of the Cardiac Effects of Danicopan in Healthy Adults Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 33 | 2018-07-26 | 2021-08-23 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
Showing 20 of 34. Sign in to see all of them.
Renal Insufficiency (2) · Alopecia Areata (1) · Cataract (1) · Glaucoma (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranoproliferative (1) · Hodgkin Disease (1) · Lupus Nephritis (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Myasthenia Gravis (1) · Parkinson Disease (1)
Alexion Pharmaceuticals, Inc. (26) · Columbia University (2) · Nektar Therapeutics (2) · Genentech, Inc. (1) · Neuramedy Co. Ltd. (1) · Oertli Instrumente AG (1) · Shire (1)
United States (24) · New Zealand (6) · United Kingdom (5) · Germany (4) · Canada (3) · Spain (3) · Australia (2) · Italy (2) · Poland (2) · Serbia (2) · South Korea (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Bulgaria (1)
Changchun Deng, MD (2) · Farhad Hafezi, MD, PhD (1) · Stuart Mair, MBChB, etc. (1)
PMID 31573880, PMID 36423588, PMID 37528520, PMID 38299639, PMID 42043793, PMID 42628554
2017 (2), 2019 (1), 2023 (1)